# Phase I Trial of Oral Metronomic Topotecan and Oral Pazopanib to Treat Recurrent/Persistent Gynecologic Tumors

> **NCT00800345** · PHASE1 · COMPLETED · sponsor: **Vector Oncology** · enrollment: 33 (actual)

## Conditions studied

- Gynecologic Tumors

## Interventions

- **DRUG:** Oral Topotecan
- **DRUG:** Pazopanib

## Key facts

- **NCT ID:** NCT00800345
- **Lead sponsor:** Vector Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-04
- **Primary completion:** 2015-06
- **Final completion:** 2015-09
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2017-03-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00800345

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00800345, "Phase I Trial of Oral Metronomic Topotecan and Oral Pazopanib to Treat Recurrent/Persistent Gynecologic Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00800345. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*